TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05795049

Intervention type: OTHER
Intervention: Stool and saliva sample collection
Description: Stool and saliva samples collection

Intervention type: OTHER
Intervention: Stool and saliva sample collection
Description: Stool and saliva samples collection

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Questionnaire on;~* demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~* IBS severity score for adults~* Hospital Anxiety and Depression scores for adults~* Somatization score for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Quality of Life as measured by the PedsQL™ GI Symptoms Module~* GI symptoms as measured by the PedsQL™ GI Symptoms Module~* Anxiety, Depression as measured by the Pediatric PROMIS®

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Questionnaire on;~* demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~* IBS severity score for adults~* Hospital Anxiety and Depression scores for adults~* Somatization score for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Quality of Life as measured by the PedsQL™ GI Symptoms Module~* GI symptoms as measured by the PedsQL™ GI Symptoms Module~* Anxiety, Depression as measured by the Pediatric PROMIS®
Study: NCT05449821

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis
Description: Serum and saliva samples will be collected from both groups for biochemical analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis
Description: Serum and saliva samples will be collected from both groups for biochemical analysis.
Study: NCT06223867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jaspr App + JAH
Description: With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ETAU
Description: Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
Study: NCT06062433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Description: Phone application and spirometer for self-management of asthma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Description: Phone application and spirometer for self-management of asthma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Description: Phone application and spirometer for self-management of asthma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma-Guidance and Prediction System
Description: Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma-Guidance and Prediction System
Description: Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma-Guidance and Prediction System
Description: Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record
Study: NCT05595148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate WBAT
Description: Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention: Delayed WBAT
Description: Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
Study: NCT05446649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumented assisted soft tissue mobilization
Description: the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
Study: NCT05386043

Intervention type: DRUG
Intervention: FET F-18
Description: PET scan with FET prior to biopsy

Intervention type: DRUG
Intervention: O-15 Radioisotope
Description: PET scan with O-15 Water prior to biopsy

Intervention type: PROCEDURE
Intervention: CT scan
Description: CT scan prior to biopsy

Intervention type: PROCEDURE
Intervention: MRI with gadolinium-based contrast
Description: MRI prior to biopsy

Intervention type: PROCEDURE
Intervention: Biopsy Collection
Description: Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision
Study: NCT06499844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
Study: NCT06501001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Three weekly, supervised exercise sessions with high intensity. Each session will last for 45 minutes. The intervention period will be sixteen weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Three weekly, supervised exercise sessions with high intensity. Each session will last for 45 minutes. The intervention period will be sixteen weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Time-Restricted Eating
Description: Restricted daily window of caloric intake to a maximum 10 hours. The intervention period will be sixteen weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Time-Restricted Eating
Description: Restricted daily window of caloric intake to a maximum 10 hours. The intervention period will be sixteen weeks.
Study: NCT06052761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Making Toys from Medical Materials
Description: Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top.
Study: NCT06245889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: additional chemotherapy - neoadjuvant or adjuvant rescue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: additional chemotherapy - adjuvant rescue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: adjuvant rescue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: adjuvant rescue
Study: NCT06464497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Foods MyPlate Group
Description: Families will receive 4-weeks of rotating menus that have been designed as a part of our preliminary work and will be adapted to support adherence with the adolescent in mind (e.g., school lunch options, on-the-go snacks). Menus and diet recommendations will align with the current macronutrient nutritional goals outlined by the 2020-2025 DGA for age-sex groups. Participants will be encouraged to eat ad libitum (i.e., as desired until full) without calorie restrictions. MyPlate will be used by participants to implement the diet. During the study, adolescents and adults in the intervention group will receive a MyPlate Plan to support daily food group and macronutrient goals that align with the whole foods diet per caloric needs.
Study: NCT04855916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Description: Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Description: Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KAFO Orthosis
Description: Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KAFO Orthosis
Description: Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
Study: NCT06230900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one
Description: (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 14C-(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one
Description: 14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
Study: NCT04921241

Intervention type: OTHER
Intervention: In Utero Exposure to SARS-CoV-2
Description: Born to mother with SARS-CoV-2 infection during pregnancy
Study: NCT06018337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV
Study: NCT05558696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral tablet
Study: NCT05023733

Intervention type: DEVICE
Intervention: CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®
Description: Patients undergoing 1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1
Study: NCT06317181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of elastography data
Description: patients who are scheduled for an elastography for clinical reasons usually receive an ultrasound scan in which the b-mode images of the liver tissue are collected. In this study additional radiofrequency data is collected through a software access.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of ultrasonic raw data
Description: Patients who are transferred to the ultrasound departement due to suspicious focal lesions receive an ultrasonic investigation including the acquisition of raw data and extracting a definitive diagnose from the following clinical routine investigation, depending on the standards of the participating center
Study: NCT04272294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Spectroscopy
Description: Using oral spectroscopy device to characterize treatment response in tumors
Study: NCT04974671

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
Study: NCT05897541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Administered as a tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a tablet.
Study: NCT06529536

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genotyping for CYP3A4 and CYP3A5 genes
Description: Genotyping: Patients in the prospective (intervention) arm will undergo genotyping using Illumina's genome-wide genotyping array (Infinium Global Screening Array).~The determined diplotypes for CYP3A5 will be matched with predicted phenotypes using the Clinical Pharmacogenetics Implementation Consortium (CPIC®) proposed genotype-to-phenotype translation table. The assignment of the phenotype is outlined in the CPIC guidelines which will used to predict initial dose of tacrolimus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of NextDose platform
Description: NextDose platform is a forecasting tool used to predict tacrolimus dosage. It is a freely available tool and will be used in accordance with guideline. The dosing recommendations will be led by the academic pharmacist in consultation with the PI. This tool will use genotype-informed Bayesian dosing to help predict the time course of tacrolimus concentrations in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is administered to all patients post SOT at RCH
Study: NCT05958251

Intervention type: OTHER
Intervention: Cicaben
Description: Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).

Intervention type: OTHER
Intervention: Standard Care (in control arm)
Description: Standard care
Study: NCT05178173

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Sterile Water
Description: Sterile Water Placebo Comparator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 27% Ethanol plus essential oils
Description: Over-the-counter antiseptic mouth rinse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.075% Cetylpyridinium Chloride
Description: Over-the-counter antiseptic mouth rinse
Study: NCT05968820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Enhancement Intervention
Description: The program is based on principles from CBT-I (time in bed restriction, stimulus control, relaxation techniques, sleep education) and includes behavioral strategies to entrain circadian rhythm, strengthen sleep homeostasis, reduce hyperarousal, and sleep hygiene techniques. Self-Determination Theory (SDT) and Social Cognitive Theory (SCT) will serve as the theoretic framework for behavior change techniques (BCT) threaded through the sleep health enhancement intervention. Participants will maintain a sleep diary during the program to aid in tailoring the program, self-monitoring of behavior, and feedback of behavior. Goals will be set by the participant at each session and reviewed at subsequent sessions, and motivational interviewing principles will be incorporated.
Study: NCT05720897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Alone
Description: Participants randomized to this arm will receive earphones to listen to an 8 minute guided brief relaxation recording, focusing on breathing and a body scan. Participants will listen to the recording prior to their dental procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation Virtual Reality
Description: Participants randomized to this arm will receive will receive virtual reality goggles and choose a scene of their liking to experience. Participants will choose from 11 different themed environments (such as savannah, beach, meadow, or space), and will experience the chosen virtual reality environment for 8 minutes. Participants will complete the virtual reality intervention prior to their dental procedure.
Study: NCT05109364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin therapy
Description: Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
Study: NCT04636814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001 1600µg
Description: CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001 3200µg
Description: CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: - 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
Study: NCT06537817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-4253
Description: HT-4253 Single or Multiple doses administered orally as a tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet
Study: NCT04930445

Intervention type: DRUG
Intervention: Oxbryta® (voxelotor) 500mg Tablets
Description: Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
Study: NCT05913882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Strength Training (LVR+EMST)
Description: Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
Study: NCT05430854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daxdilimab
Description: Daxdilimab will be administered subcutaneously as two injections for each dose.
Study: NCT06057753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyStroke
Description: Personalized video-based stroke education platform